StreetInsider.com News Articles

BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study

Tue, 08 Sep 2026 03:05:00 -0400

VANCOUVER, BC / ACCESS Newswire / September 8, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the advancement of its proprietary sublingual Everolimus oral dissolvable film ("ODF") program, initially targeting organ transplantation, with a comparative large-animal pharmacokinetic study.

Everolimus test materials have been prepared for shipment to a preclinical research facility in China for a planned pharmacokinetic ("PK") study comparing two proprietary sublingual Everolimus formulations with an orally administered 1 mg Everolimus reference product. The study represents an

BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study

Tue, 08 Sep 2026 03:05:00 -0400

BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study

Tue, 08 Sep 2026 03:05:00 -0400

BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study

Tue, 08 Sep 2026 03:05:00 -0400

BioNxt Advances Cladribine Clinical Program for MS with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies

Wed, 26 Aug 2026 03:05:00 -0400

VANCOUVER, BC / ACCESS Newswire / August 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the completion of the Investigational Medicinal Product Dossier ("IMPD") for BNT23001, the Company's lead proprietary sublingual cladribine oral dissolvable film (ODF) product candidate for the treatment of relapsing forms of multiple sclerosis (MS). Completion of the IMPD represents a significant regulatory milestone and advances BioNxt's lead development program toward its planned first human bioequivalence study.

The IMPD is currently undergoing final technical

BioNxt Advances Cladribine Clinical Program for MS with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies

Wed, 26 Aug 2026 03:05:00 -0400

The IMPD is currently undergoing final technical

BioNxt Solutions Inc. Announces Closing of Extension of Convertible Debentures and Issuance of Warrants

Fri, 21 Aug 2026 18:30:00 -0400

VANCOUVER, BC / ACCESS Newswire / August 21, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT) is pleased to announce that it has closed its previously announced extension of unsecured convertible debentures (the "Debentures"), as initially disclosed in its news releases dated June 10 and 23, 2026.

The Company amended the terms of the Debentures in the principal amounts of $425,000, $285,000, $1,400,000, $865,000, $1,600,000, and $900,000, bearing interest at a rate of 8% per annum to extend the maturity dates of the Debentures by one year to November 12, 2027,

BioNxt Solutions Inc. Announces Closing of Extension of Convertible Debentures and Issuance of Warrants

Fri, 21 Aug 2026 18:30:00 -0400

BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies

Wed, 19 Aug 2026 03:05:00 -0400

VANCOUVER, BC / ACCESS Newswire / August 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the completion of the Investigational Medicinal Product Dossier ("IMPD") for BNT23001, the Company's lead proprietary sublingual cladribine oral dissolvable film (ODF) product candidate for the treatment of relapsing forms of multiple sclerosis (MS). Completion of the IMPD represents a significant regulatory milestone and advances BioNxt's lead development program toward its planned first human bioequivalence study.

The IMPD is currently undergoing final technical

BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies

Wed, 19 Aug 2026 03:05:00 -0400

The IMPD is currently undergoing final technical

BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline

Mon, 17 Aug 2026 06:40:00 -0400

VANCOUVER, BC / ACCESS Newswire / August 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to provide a comprehensive update on the progress of its proprietary sublingual thin-film drug delivery pipeline. The Company continues to advance multiple pharmaceutical development programs, including Cladribine for multiple sclerosis, autoimmune disease expansion, Everolimus and Semaglutide, while strengthening the intellectual property portfolio supporting its platform and preparing for the next phase of clinical and commercial development.

"Our vision has always been to build a

BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline

Mon, 17 Aug 2026 06:40:00 -0400

VANCOUVER, BC / ACCESS Newswire / August 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to provide a comprehensive update on the progress of its proprietary sublingual thin-film drug delivery pipeline. The Company continues to advance multiple pharmaceutical development programs, including Cladribine for multiple sclerosis, autoimmune disease expansion, Everolimus and Semaglutide, while strengthening the intellectual property portfolio supporting its platform and preparing for the next phase of clinical and commercial development.
"Our vision has always been to build a

BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline

Tue, 04 Aug 2026 03:05:00 -0400

VANCOUVER, BC / ACCESS Newswire / August 4, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to provide a comprehensive update on the progress of its proprietary sublingual thin-film drug delivery pipeline. The Company continues to advance multiple pharmaceutical development programs, including Cladribine for multiple sclerosis, autoimmune disease expansion, Everolimus and Semaglutide, while strengthening the intellectual property portfolio supporting its platform and preparing for the next phase of clinical and commercial development.
"Our vision has always been to build a

BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline

Tue, 04 Aug 2026 03:05:00 -0400

VANCOUVER, BC / ACCESS Newswire / August 4, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to provide a comprehensive update on the progress of its proprietary sublingual thin-film drug delivery pipeline. The Company continues to advance multiple pharmaceutical development programs, including Cladribine for multiple sclerosis, autoimmune disease expansion, Everolimus and Semaglutide, while strengthening the intellectual property portfolio supporting its platform and preparing for the next phase of clinical and commercial development.
"Our vision has always been to build a

BioNxt Solutions Announces Option Grants

Fri, 31 Jul 2026 18:25:00 -0400

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, BC / ACCESS Newswire / July 31, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT) announces that it has granted an aggregate of 750,000 stock options ("Options") pursuant to the Company's stock option plan (the "Option Plan") to certain insiders, consultants and an employee of the Company, each Option entitling the holder thereof to acquire one common share of the Company (a "Common Share") at an exercise price of $0.33 for a period

BioNxt Solutions Announces Option Grants

Fri, 31 Jul 2026 18:25:00 -0400

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, BC / ACCESS Newswire / July 31, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT) announces that it has granted an aggregate of 750,000 stock options ("Options") pursuant to the Company's stock option plan (the "Option Plan") to certain insiders, consultants and an employee of the Company, each Option entitling the holder thereof to acquire one common share of the Company (a "Common Share") at an exercise price of $0.33 for a period

BioNxt closes $2M private placement at $0.33 per unit

Tue, 23 Jun 2026 17:20:09 -0400

BioNxt Solutions Inc. (CSNX: BNXT)(OTCQB: BNXTF)(FSE: BXT) has closed a non-brokered private placement under the Listed Issuer Financing Exemption, issuing 6,060,606 units at $0.33 each for gross proceeds of approximately $2 million.

Each unit consists of one common share and one share purchase warrant. Each warrant allows the holder to purchase one additional share at $0.50 for 24 months from the closing date. The securities issued are not subject to a hold period under applicable Canadian securities laws.

The company paid $120,000 in cash finder's fees and issued 363,636 non-transferable finder's warrants to an arm's length finder, also exercisable at $0.50 per

BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption

Tue, 23 Jun 2026 17:20:00 -0400

Not for distribution to U.S. newswire services or for dissemination in the United States.

VANCOUVER, BC / ACCESS Newswire / June 23, 2026 / BioNxt Solutions Inc. (CSNX:BNXT)(OTCQB:BNXTF)(FSE:BXT) (the "Company" or "BioNxt") is pleased to announce that it has closed its previously announced non-brokered private placement (the "LIFEOffering") of units of the Company ("Units") pursuant to the Listed Issuer Financing exemption available under Part 5A of National Instrument 45-106 - Prospectus Exemptions. Pursuant to the LIFE Offering, the Company issued an aggregate of 6,060,606 Units at a price of $0.33 per Unit

BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption

Tue, 23 Jun 2026 17:20:00 -0400

Not for distribution to U.S. newswire services or for dissemination in the United States.

VANCOUVER, BC / ACCESS Newswire / June 23, 2026 / BioNxt Solutions Inc. (CSNX:BNXT)(OTCQB:BNXTF)(FSE:BXT) (the "Company" or "BioNxt") is pleased to announce that it has closed its previously announced non-brokered private placement (the "LIFEOffering") of units of the Company ("Units") pursuant to the Listed Issuer Financing exemption available under Part 5A of National Instrument 45-106 - Prospectus Exemptions. Pursuant to the LIFE Offering, the Company issued an aggregate of 6,060,606 Units at a price of $0.33 per Unit

BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF

Mon, 15 Jun 2026 03:45:00 -0400

VANCOUVER, BC / ACCESS Newswire / June 15, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that it has commenced work with a Business Development & Licensing ("BD&L") specialist advisor to support the commercialization and partnering strategy for BNT23001, the Company's patented proprietary sublingual Cladribine orally dissolvable film ("ODF") formulation for the treatment of multiple sclerosis ("MS").
BNT23001 is designed as a differentiated alternative to conventional tablet-based Cladribine therapy, including Mavenclad^®, by offering a thin, dissolvable film placed

BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF

Mon, 15 Jun 2026 03:45:00 -0400

VANCOUVER, BC / ACCESS Newswire / June 15, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that it has commenced work with a Business Development & Licensing ("BD&L") specialist advisor to support the commercialization and partnering strategy for BNT23001, the Company's patented proprietary sublingual Cladribine orally dissolvable film ("ODF") formulation for the treatment of multiple sclerosis ("MS").
BNT23001 is designed as a differentiated alternative to conventional tablet-based Cladribine therapy, including Mavenclad^®, by offering a thin, dissolvable film placed

BioNxt Solutions Inc. Announces Extension of Convertible Debentures and Issuance of Warrants

Wed, 10 Jun 2026 18:30:00 -0400

VANCOUVER, BC / ACCESS Newswire / June 10, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT) announces that it has amended the terms of previously issued unsecured convertible debentures in the principal amounts of $425,000, $285,000, $1,400,000, $865,000, $1,600,000, and $900,000, bearing interest at a rate of 8% per annum and maturing on November 12, 2026, November 29, 2026, December 19, 2026, January 14, 2027, February 28, 2027, and March 14, 2027, respectively (the "Debentures").
The Company has amended the Debenturesto extend the maturity dates of the Debentures by one year

BioNxt Solutions Inc. Announces Extension of Convertible Debentures and Issuance of Warrants

Wed, 10 Jun 2026 18:30:00 -0400

VANCOUVER, BC / ACCESS Newswire / June 10, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT) announces that it has amended the terms of previously issued unsecured convertible debentures in the principal amounts of $425,000, $285,000, $1,400,000, $865,000, $1,600,000, and $900,000, bearing interest at a rate of 8% per annum and maturing on November 12, 2026, November 29, 2026, December 19, 2026, January 14, 2027, February 28, 2027, and March 14, 2027, respectively (the "Debentures").
The Company has amended the Debenturesto extend the maturity dates of the Debentures by one year

BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development

Tue, 19 May 2026 03:05:00 -0400

VANCOUVER, BC / ACCESS Newswire / May 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that its Semaglutide oral dissolvable film ("ODF") program has entered the active pharmaceutical development phase in collaboration with German drug development partner Gen-Plus GmbH.
The advancement represents a significant strategic milestone for BioNxt as the Company applies its expertise in sublingual thin-film drug delivery systems beyond neurological and autoimmune diseases into the rapidly growing global GLP-1 therapeutics market.
Applying BioNxt's Thin-Film Expertise to

BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development

Tue, 19 May 2026 03:05:00 -0400

VANCOUVER, BC / ACCESS Newswire / May 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that its Semaglutide oral dissolvable film ("ODF") program has entered the active pharmaceutical development phase in collaboration with German drug development partner Gen-Plus GmbH.
The advancement represents a significant strategic milestone for BioNxt as the Company applies its expertise in sublingual thin-film drug delivery systems beyond neurological and autoimmune diseases into the rapidly growing global GLP-1 therapeutics market.
Applying BioNxt's Thin-Film Expertise to